Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Abstract Introduction This study assessed the cost-effectiveness of ozanimod compared with commonly used disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS). Methods Annualized relapse rate (ARR) and safety data were obtained from a network meta-analysis (NMA) of cli...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daniel Kantor, Timothy Pham, Oscar Patterson-Lomba, Elyse Swallow, Akanksha Dua, Komal Gupte-Singh
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2023-03-01
coleção:	Neurology and Therapy
Assuntos:	Ozanimod Relapsing–remitting multiple sclerosis Cost-effectiveness analysis Disease-modifying therapies
Acesso em linha:	https://doi.org/10.1007/s40120-023-00463-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!